NEW YORK--(BUSINESS WIRE)--Deliberate AI, a digital health technology company that delivers precision measurement of mental health through AI, today announced its inclusion in the U.S. Food and Drug Administration (FDA) Innovative Science and Technology Approaches for New Drugs (ISTAND) Pilot Program. Under the program, Deliberate AI’s assessment tool for anxiety and depression, the AI-generated Clinical Outcome Assessment or AI-COA™, will receive support to become a qualified drug development tool (DDT). The company’s AI-enabled assessment tool leverages cutting-edge multimodal behavioral signal processing and machine learning to quantitatively capture mental health symptoms, offering a consistent, bias-free assessment method. During clinical trials, it augments human clinical assessments with its AI algorithm, to improve precision and reliability. This pivotal endorsement marks Deliberate AI technology as the FDA’s first AI/ML and Digital Health Technology (DHT) initiative, as well as the inaugural project in the fields of Psychiatry and Neuroscience, to join the pilot program

What You Should Know:– Deliberate AI, a digital health company harnessing AI to revolutionize mental health assessment, has secured a major milestone in its mission. The U.S. Food and Drug Administration (FDA) has selected Deliberate AI’s AI-generated Clinical Outcome Assessment (AI-COA™) for its Innovative Science and Technology Approaches for New Drugs (ISTAND) Pilot Program.– The collaboration between Deliberate AI and the FDA represents a giant leap in the fight against mental illness. By harnessing the power of AI, we can accelerate drug development, improve treatment efficacy, and ultimately empower patients to live healthier, happier livesAI-COA™: A Beacon of Precision in Mental HealthDeliberate AI’s AI-COA™ leverages cutting-edge multimodal signal processing and machine learning to capture mental health symptoms quantitatively. This novel approach offers several advantages over traditional methods:Objectivity and consistency: AI-COA™ removes human bias and subjectivity, providing a consistent and reliable assessment method.AI-COA™ removes human bias and subjectivity, providing a consistent and reliable assessment method. Enhanced precision: The AI algorithm analyzes subtle behavioral cues, offering a more granular picture of symptom severity than traditional questionnaires.The AI algorithm analyzes subtle behavioral cues, offering a more granular picture of symptom severity than traditional questionnaires